Cedar Fair LP
Change company Symbol lookup
Select an option...
FUN Cedar Fair LP
NWFFX American Funds New World Fund® Class F-1
CARS Cars.com Inc
AHT Ashford Hospitality Trust Inc
AHII Fyolo Technology Corp
AHH-A Armada Hoffler Properties Inc
AHH Armada Hoffler Properties Inc
AHFD Active Health Foods Inc
AGSO AgriSolar Solutions Inc
AGS PlayAGS Inc
Go

Consumer Discretionary : Hotels, Restaurants & Leisure | Small Cap Value
Company profile

Cedar Fair, L.P. is an operator of regional amusement parks. The Company operates within a segment of amusement/water parks with accompanying resort facilities. As of December 31, 2016, the Company owned approximately 11 amusement parks, two separately gated outdoor water parks, one indoor water park and five hotels. The amusement parks include Cedar Point, located on Lake Erie between Cleveland and Toledo in Sandusky, Ohio; Knott's Berry Farm, near Los Angeles, California; Canada's Wonderland, near Toronto, Canada; Kings Island, near Cincinnati, Ohio; Carowinds, in Charlotte, North Carolina; Dorney Park & Wildwater Kingdom (Dorney Park), in Allentown, Pennsylvania; Kings Dominion, near Richmond, Virginia; California's Great America, in Santa Clara, California; Valleyfair, near Minneapolis/St. Paul, Minnesota; Worlds of Fun, in Kansas City, Missouri, and Michigan's Adventure, in Muskegon, Michigan. It manages and operates Gilroy Gardens Family Theme Park in Gilroy, California.

Closing Price
$29.90
Day's Change
0.10 (0.34%)
Bid
--
Ask
--
B/A Size
--
Day's High
30.20
Day's Low
29.25
Volume
(Below Average)
Volume:
402,329

10-day average volume:
501,475
402,329

Pfizer's stock surges after profit and revenue beats, raised guidance

6:58 am ET July 28, 2020 (MarketWatch)
Print

Shares of Pfizer Inc. (PFE) surged 3.4% in premarket trading Tuesday, after the drug maker reported profit and revenue that beat expectations and raised its full-year outlook, despite the challenges resulting from the COVID-19 pandemic. The results come after Pfizer and BioNTech SE (BNTX) said late Monday that a late-stage trial of its COVID-19 vaccine candidate (http://www.marketwatch.com/story/pfizer-biontechs-covid-vaccine-candidate-enters-late-stage-trial-2020-07-27) has started. Pfizer reported net income that fell to $3.43 billion, or 61 cents a share, from $5.05 billion, or 89 cents a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share fell to 78 cents form 80 cents but beat the FactSet consensus of 67 cents. Revenue declined 11% to $11.80 billion but was above the FactSet consensus of $11.58 billion. Biopharma revenue rose 4% to $9.80 billion while Upjohn revenue dropped 32% to $2.01 billion. For 2020, the company raised its guidance ranges for adjusted EPS to $2.85 to $2.95 from $2.82 to $2.92 and for revenue to $48.6 billion to $50.6 billion from $48.5 billion to $50.5 billion. The stock has slipped 4.2% year to date through Monday, while the Dow Jones Industrial Average has declined 6.9%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 28, 2020 06:58 ET (10:58 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.